TerminatedPhase 2NCT05415410
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
Studying Rare disorder potentially indicated for transplant or complication after transplantation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- VectivBio AG
- Principal Investigator
- Tomasz MasiorVectivBio AG
- Intervention
- Apraglutide(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2024
Study locations (13)
- Stanford Cancer Center, Stanford, California, United States
- University of Iowa, Iowa City, Iowa, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- The Ohio State University, Columbus, Ohio, United States
- South Austin Medical Center, Austin, Texas, United States
- Universitätsklinikum Köln (AoeR), Cologne, Germany
- Universitaetsklinikum Duesseldorf, Düsseldorf, Germany
- Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany
- Martin Luther Universität Halle-Wittenberg, Halle, Germany
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- Universitätsmedizin der Johannes Gutenberg - Universität Mainz, Mainz, Germany
- Instituto Portugues de Oncologia do Porto Francisco Gentil, Porto, Portugal
- Hospital Universitario Virgen del Rocio, Seville, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05415410 on ClinicalTrials.govOther trials for Rare disorder potentially indicated for transplant or complication after transplantation
Additional recruiting or active studies for the same condition.